Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update
Portage Biotech Inc. (NASDAQ: PRTG) reported financial results for the fiscal year ended March 31, 2024. The company incurred a net loss of $75.4 million, down from $104.7 million in the previous year. Operating expenses increased to $18.2 million, with R&D costs rising 44% to $12.5 million. The company is exploring strategic alternatives, including potential partnerships, sale, or restructuring. Portage has discontinued its iNKT clinical trial for PORT-2 and paused enrollment in the ADPORT-601 trial for PORT-6 and PORT-7. As of March 31, 2024, Portage had $5.0 million in cash and cash equivalents and $2.9 million in current liabilities.
Portage Biotech Inc. (NASDAQ: PRTG) ha riportato i risultati finanziari per l'anno fiscale concluso il 31 marzo 2024. L'azienda ha registrato una perdita netta di 75,4 milioni di dollari, in calo rispetto ai 104,7 milioni di dollari dell'anno precedente. Le spese operative sono aumentate a 18,2 milioni di dollari, con i costi di ricerca e sviluppo che sono aumentati del 44% a 12,5 milioni di dollari. L'azienda sta esplorando alternative strategiche, incluse potenziali collaborazioni, vendita o ristrutturazione. Portage ha interrotto il suo trial clinico iNKT per PORT-2 e ha sospeso l'arruolamento nella sperimentazione ADPORT-601 per PORT-6 e PORT-7. Al 31 marzo 2024, Portage disponeva di 5,0 milioni di dollari in cassa e equivalenti e 2,9 milioni di dollari in passività correnti.
Portage Biotech Inc. (NASDAQ: PRTG) informó los resultados financieros para el año fiscal que terminó el 31 de marzo de 2024. La compañía tuvo una pérdida neta de 75,4 millones de dólares, una disminución respecto a los 104,7 millones de dólares del año anterior. Los gastos operativos aumentaron a 18,2 millones de dólares, con los costos de I+D aumentando un 44% a 12,5 millones de dólares. La compañía está explorando alternativas estratégicas, incluyendo asociaciones potenciales, venta o reestructuración. Portage ha descontinuado su ensayo clínico iNKT para PORT-2 y ha pausado la inscripción en el ensayo ADPORT-601 para PORT-6 y PORT-7. Al 31 de marzo de 2024, Portage tenía 5,0 millones de dólares en efectivo y equivalentes y 2,9 millones de dólares en pasivos corrientes.
포티지 바이오텍(Portage Biotech Inc.)(NASDAQ: PRTG)는 2024년 3월 31일로 종료된 회계연도의 재무 결과를 보고했습니다. 이 회사는 7540만 달러의 순손실을 기록했으며, 이는 전년도 1억 470만 달러에서 감소한 수치입니다. 운영 비용은 1820만 달러로 증가했으며, 연구개발 비용은 44% 증가하여 1250만 달러에 달했습니다. 이 회사는 전략적 대안을 탐색 중이며, 잠재적 파트너십, 매각 또는 구조조정을 포함하고 있습니다. 포티지는 PORT-2에 대한 iNKT 임상 시험을 중단했습니다 그리고 PORT-6 및 PORT-7에 대한 ADPORT-601 시험의 등록을 일시 중지했습니다. 2024년 3월 31일 기준으로 포티지는 500만 달러의 현금 및 현금성 자산과 290만 달러의 유동 부채를 보유하고 있었습니다.
Portage Biotech Inc. (NASDAQ: PRTG) a annoncé les résultats financiers pour l'exercice clos le 31 mars 2024. L'entreprise a enregistré une perte nette de 75,4 millions de dollars, en baisse par rapport à 104,7 millions de dollars l'année précédente. Les charges d'exploitation ont augmenté à 18,2 millions de dollars, tandis que les coûts de R&D ont crû de 44 % pour atteindre 12,5 millions de dollars. L'entreprise explore des alternatives stratégiques, y compris des partenariats potentiels, une vente ou une restructuration. Portage a interrompu son essai clinique iNKT pour PORT-2 et a suspendu l'inscription à l'essai ADPORT-601 pour PORT-6 et PORT-7. Au 31 mars 2024, Portage disposait de 5,0 millions de dollars en espèces et équivalents et de 2,9 millions de dollars de passifs courants.
Portage Biotech Inc. (NASDAQ: PRTG) hat die finanziellen Ergebnisse für das am 31. März 2024 abgelaufene Geschäftsjahr veröffentlicht. Das Unternehmen verzeichnete einen Jahresfehlbetrag von 75,4 Millionen Dollar, eine Reduzierung im Vergleich zu 104,7 Millionen Dollar im Vorjahr. Die Betriebsausgaben stiegen auf 18,2 Millionen Dollar, während die F&E-Kosten um 44 % auf 12,5 Millionen Dollar anstiegen. Das Unternehmen prüft strategische Alternativen, darunter potenzielle Partnerschaften, Verkäufe oder Umstrukturierungen. Portage hat die iNKT-Studie für PORT-2 eingestellt und die Einschreibung in die ADPORT-601-Studie für PORT-6 und PORT-7 ausgesetzt. Zum 31. März 2024 verfügte Portage über 5,0 Millionen Dollar in Bargeld und liquiden Mitteln sowie 2,9 Millionen Dollar an kurzfristigen Verbindlichkeiten.
- Net loss decreased by $29.3 million year-over-year
- Recognized a $6.9 million non-cash gain from change in fair value of certain warrants
- Recognized a $0.7 million gain on the sale of Intensity shares
- Net loss of $75.4 million for fiscal year 2024
- Operating expenses increased by $1.6 million to $18.2 million
- R&D costs increased by 44% to $12.5 million
- Discontinued iNKT clinical trial and paused ADPORT-601 trial enrollment
- Impairment of intangible assets totaling $81.5 million
- Cash and cash equivalents decreased to $5.0 million
Insights
Portage Biotech's fiscal year 2024 results reveal significant challenges. The company reported a net loss of
The increase in R&D expenses by
With only
The discontinuation of the iNKT clinical trial for PORT-2 and the pausing of patient enrollment in the ADPORT-601 trial (adenosine 2A and 2B inhibitors) are significant setbacks for Portage's pipeline. These decisions, driven by funding constraints, effectively halt the company's primary clinical programs.
The full impairment of in-process R&D for iOx (
While the company's multi-targeted therapies showed promise, the current financial situation has forced a re-evaluation of their clinical development strategy. This pivot could significantly delay any potential breakthroughs in immuno-oncology treatments that Portage was pursuing.
Portage Biotech's strategic shift signals a critical inflection point for the company. The exploration of alternatives, including potential partnerships, sale, or merger, indicates a recognition that the current business model may not be sustainable.
The discontinuation and pausing of clinical trials could significantly impact Portage's market position in the competitive immuno-oncology field. This move might lead to a loss of confidence among potential partners or investors, making future funding rounds more challenging.
The
Investors should closely monitor Portage's ability to secure strategic partnerships or complete a favorable M&A transaction, as these outcomes could significantly impact the company's future prospects and shareholder value.
- Exploration and evaluation of strategic alternatives continue
- Pausing patient enrollment in the ADPORT-601 clinical trial (adenosine 2A and 2B inhibitors)
- Discontinuing the iNKT clinical trial for PORT-2
WESTPORT, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today announced its financial results for the fiscal year ended March 31, 2024.
“After reviewing Portage’s funding requirements, which necessitated discontinuing the clinical development of its iNKT program and pausing patient enrollment in the ADPORT-601 clinical trial of PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor), we continue to explore strategic alternatives. These may include finding a partner for one or more of our assets, a sale of our company, a merger, restructurings (both in and out of court), a company wind down, further financing efforts, or other strategic actions,” said Dr. Ian Walters, Chief Executive Officer and Chairman of Portage.
Financial Results from Year Ended March 31, 2024
The Company incurred a net loss of approximately
Operating expenses, which include research and development (“R&D”) costs and general and administrative (“G&A”) expenses, were
R&D costs increased by approximately
G&A expenses decreased by approximately
The Company’s other pre-tax items of income and expense were substantially non-cash in nature, aggregating approximately
The Company recognized a
Additionally, the Company recognized a non-cash net deferred income tax benefit of
As of March 31, 2024, the Company had cash and cash equivalents of approximately
About Portage Biotech Inc.
Portage is a clinical-stage immuno-oncology company advancing multi-targeted therapies to extend survival and significantly improve the lives of patients with cancer. The Company has made the decision to discontinue its sponsored trial for its the invariant natural killer T-cell (iNKT) program and pause patient enrollment to its sponsored adenosine trial program (ADPORT-601 trial) for its potentially best-in-class adenosine antagonists PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor). The Company is exploring strategic alternatives, which may include finding a partner for one or more of its assets, a sale of the company, a merger, restructurings, both in and out of court, a company wind down, further financing efforts or other strategic action. For more information, please visit www.portagebiotech.com, follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc.
Forward-Looking Statements
All statements in this news release, other than statements of historical facts, including without limitation, statements regarding about the Company’s information that are forward-looking in nature and, business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or that otherwise include the words "believe," "expects," "anticipates," "intends," "estimates," “will,” “may,” “plan,” “potential,” “continue,” or similar expressions or variations on such expressions are forward-looking statements. For example, statements regarding the Company's plans to continue exploring strategic alternatives, which may include finding a partner for one or more of its assets, a sale of the company, a merger, restructurings (both in and out of court), a company wind down, further financing efforts, or other strategic actions, are forward-looking statements. As a result, forward-looking statements are subject to certain risks and uncertainties, including, but are not limited to: the Company's plans and ability to develop and commercialize product candidates and the timing of these development programs; the Company's clinical development of its product candidates, including the results of current and future clinical trials; the benefits and risks of the Company's product candidates as compared to others; the Company's maintenance and establishment of intellectual property rights in its product candidates; the Company's ability to obtain financing in the future to cover its operational costs and progress its plans for clinical development, its estimates regarding its capital requirements, and its ability to continue as a going concern; the Company’s estimates of future revenues and profitability; the Company's estimates of the size of the potential markets for its product candidates; its selection and licensing of product candidates; and other factors set forth in “Item 3 - Key Information-Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended March 31, 2024. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations:
ir@portagebiotech.com
Media Relations:
media@portagebiotech.com
---tables to follow---
PORTAGE BIOTECH INC. Consolidated Statements of Operations and Other Comprehensive Income (Loss) (U.S. Dollars in thousands, except per share amounts) | ||||||||||
Years Ended March 31, | ||||||||||
2024 | 2023 | 2022 | ||||||||
Expenses | ||||||||||
Research and development | $ | 12,535 | $ | 8,674 | $ | 6,769 | ||||
General and administrative expenses | 5,664 | 7,901 | 8,819 | |||||||
Loss from operations | (18,199 | ) | (16,575 | ) | (15,588 | ) | ||||
Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone | 11,305 | 2,711 | – | |||||||
Loss on Registered Direct Offering | (2,432 | ) | – | – | ||||||
Offering costs | (662 | ) | – | – | ||||||
Change in fair value of warrant liability | 6,868 | 33 | 852 | |||||||
Impairment loss - iOx IPR&D | (57,890 | ) | (59,320 | ) | – | |||||
Impairment loss - Tarus IPR&D | (23,615 | ) | (4,585 | ) | – | |||||
Impairment loss - Goodwill | – | (43,862 | ) | – | ||||||
Impairment loss - Stimunity | (1,002 | ) | (818 | ) | – | |||||
Impairment loss - Saugatuck | (178 | ) | – | – | ||||||
Commitment fee under Committed Purchase Agreement | (839 | ) | – | – | ||||||
Share of loss in associate accounted for using equity method | (233 | ) | (260 | ) | (62 | ) | ||||
Gain on dissolution of investment in associate | 27 | – | – | |||||||
Gain from sale of investment in public company | 725 | – | – | |||||||
Foreign exchange transaction gain (loss) | 7 | (53 | ) | 24 | ||||||
Depreciation expense | (54 | ) | (1 | ) | – | |||||
Interest income | 274 | 217 | – | |||||||
Interest expense | (32 | ) | (9 | ) | (43 | ) | ||||
Loss before provision for income taxes | (85,930 | ) | (122,522 | ) | (14,817 | ) | ||||
Income tax benefit (expense) | 10,548 | 17,856 | (4,352 | ) | ||||||
Net loss | (75,382 | ) | (104,666 | ) | (19,169 | ) | ||||
Other comprehensive income (loss) | ||||||||||
Net unrealized loss on investments | (38 | ) | (5,283 | ) | – | |||||
Total comprehensive loss for year | $ | (75,420 | ) | $ | (109,949 | ) | $ | (19,169 | ) | |
Net loss attributable to: | ||||||||||
Owners of the Company | $ | (75,339 | ) | $ | (104,611 | ) | $ | (16,870 | ) | |
Non-controlling interest | (43 | ) | (55 | ) | (2,299 | ) | ||||
Net loss | $ | (75,382 | ) | $ | (104,666 | ) | $ | (19,169 | ) | |
Comprehensive loss attributable to: | ||||||||||
Owners of the Company | $ | (75,377 | ) | $ | (109,894 | ) | $ | (16,870 | ) | |
Non-controlling interest | (43 | ) | (55 | ) | (2,299 | ) | ||||
Total comprehensive loss for year | $ | (75,420 | ) | $ | (109,949 | ) | $ | (19,169 | ) | |
Loss per share | ||||||||||
Basic and diluted | $ | (3.89 | ) | $ | (6.49 | ) | $ | (1.29 | ) | |
Weighted average shares outstanding | ||||||||||
Basic and diluted | 19,343 | 16,119 | 13,060 |
PORTAGE BIOTECH INC. Consolidated Statements of Financial Position (U.S. Dollars in thousands) | ||||||||
March 31, | ||||||||
2024 | 2023 | |||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 5,028 | $ | 10,545 | ||||
Prepaid expenses and other receivables | 2,667 | 2,689 | ||||||
Convertible note receivable | – | 442 | ||||||
Total current assets | 7,695 | 13,676 | ||||||
Non-current assets | ||||||||
Investment in associate | – | 806 | ||||||
Investment in public company | – | 2,087 | ||||||
In-process research and development | – | 81,683 | ||||||
Deferred commitment fee, net of amortization of | – | 839 | ||||||
Right to use asset | 35 | – | ||||||
Other assets, including equipment, net | 49 | 38 | ||||||
Total non-current assets | 84 | 85,453 | ||||||
Total assets | $ | 7,779 | $ | 99,129 | ||||
Liabilities and Equity | ||||||||
Current liabilities | ||||||||
Accounts payable and accrued liabilities | $ | 2,836 | $ | 1,865 | ||||
Lease liability - current, including interest | 40 | – | ||||||
Other current liabilities | 3 | – | ||||||
Total current liabilities | 2,879 | 1,865 | ||||||
Non-current liabilities | ||||||||
Lease liability - non-current | 7 | – | ||||||
Warrant liability | 1,564 | – | ||||||
Deferred tax liability | – | 10,564 | ||||||
Deferred purchase price payable - Tarus | – | 7,179 | ||||||
Deferred obligation - iOx milestone | – | 4,126 | ||||||
Total non-current liabilities | 1,571 | 21,869 | ||||||
Total liabilities | 4,450 | 23,734 | ||||||
Shareholders’ Equity | ||||||||
Capital stock | 219,499 | 218,782 | ||||||
Stock option reserve | 23,841 | 21,204 | ||||||
Accumulated other comprehensive loss | – | (4,325 | ) | |||||
Accumulated deficit | (239,318 | ) | (159,616 | ) | ||||
Total equity attributable to owners of the Company | 4,022 | 76,045 | ||||||
Non-controlling interest | (693 | ) | (650 | ) | ||||
Total equity | 3,329 | 75,395 | ||||||
Total liabilities and equity | $ | 7,779 | $ | 99,129 | ||||
Commitments and Contingent Liabilities |
FAQ
What was Portage Biotech's net loss for fiscal year 2024?
How much cash does Portage Biotech (PRTG) have as of March 31, 2024?
What strategic alternatives is Portage Biotech (PRTG) exploring?